DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, today announced the launch of InnoSyn™ route scouting services. In response to the increasing interest of pharmaceutical customers to outsource the development of robust low-cost manufacturing routes, DSM is offering focused and flexible stand alone route scouting services. DSM's route scouting capabilities lead to significant cost savings by the reduction of synthesis steps or redesign of synthesis routes.
The InnoSyn™ route scouting team supports research and development, and the implementation of economical and scalable routes. Unique value creating solutions are provided by integrating the full range of enabling DSM competencies such as biocatalysis, homogeneous catalysis, organic synthesis and continuous chemistry using for example micro reactors. These capabilities to rapidly screen a wide variety of catalysts speed up feasibility studies for chemocatalytic and biocatalytic steps.
Recent success stories have introduced new efficient enzymes, such as pharmaPLE®, lyases, transaminases, dehydrogenases and new, easily accessible homogeneous catalysts for asymmetric hydrogenations, aromatic substitutions, and oxidations. Furthermore, a safe and clean nitration reaction was implemented under cGMP for manufacturing of an API based on DSM's micro reactor technology. InnoSyn™services are based in DSM's Geleen, The Netherlands R&D facilities and utilize DSM's wide range of technology and production sites across Europe.
Oliver May, Ph.D., Business Manager InnoSyn™ route scouting services commented, "DSM is recognized as a reliable and leading large scale cGMP manufacturer for registered intermediates and active pharmaceutical ingredients. This remains our focus but we also want to continuously serve changing customer needs whenever DSM can provide real value. Due to the reduced focus and resources in process R&D within our customers' operations there is an increasing demand for developing flexible and robust 'technology packages' ready to implement at large scale. The new DSM InnoSyn™ route scouting services are setup to address exactly this specific need based on DSM's broad and unique technology toolbox. Please visit us at CPhI Worldwide Oct 5-7 in Paris to learn more about the value we provide in this area."
Dr. May will be speaking at 13:00 PM on Tuesday, October 5th at the global CPhI Worldwide conference in Paris.
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status